Amylyx Pharmaceuticals has formally announced that Relyvrio (sodium phenylbutyrate and taurursodiol) is no longer available to new patients as of April 4, 2024. Amylyx has initiated a process with the U.S. Food and Drug Administration (FDA) to voluntarily discontinue the drug and remove it from the market.
According to a press release from the manufacturer, patients currently receiving treatment who, in consultation with their physician, wish to continue can be transitioned to a free drug program.
As a result of this announcement, Relyvrio is no longer covered at point-of-sale, effective April 4, 2024 and the product will be removed from the NC Medicaid Preferred Drug List (PDL).